After the satisfactory results obtained from various trials of Butylbenisothiazolene, preliminary clinical trials were conducted. Seven conditions where monotherapy without a permeation enhancer yielded unsatisfactory results (dermatitis, tinea manuum/pedis, tinea cruris, eczema, acne, and multiple folliculitis) were selected. The treatment was modified by incorporating 1% Butylbenisothiazolene into the medication. Five formulations were tested (ointment, cream, lotion, aqueous solution, and plaster). The trial results demonstrated that all 75 cases showed varying degrees of improved efficacy. Among these, triamcinolone acetonide ointment demonstrated the most pronounced efficacy against eczema, with noticeable improvement observed as early as the second day post-application. Post-treatment skin appeared indistinguishable from healthy skin. However, it is crucial to note that petroleum-based products such as Vaseline must not be incorporated into the formulation, as this would diminish or entirely negate the permeation-enhancing effect of the agent.
